Given that the share price could reach $18 within a year, I think it would be insane to sell for that. The reason why we haven't been bought out is because we value our company much higher than big pharma. By the time our valuations are close enough for a deal, they won't be able to afford us.

The potential of all indications could create a share price in excess of 10x that figure. Once we are to revenue, which could be in a matter of months the value goes up and the willingness to sell decreases.